Elektra Health Clinical Gaps and Limitations: What This Menopause Platform Misses

What Elektra Health Actually Offers

Elektra Health positions itself as a menopause-focused virtual care platform that pairs patients with providers trained in midlife hormonal changes. The company accepts select insurance plans and offers cash-pay visits, with an emphasis on education, community content, and one-on-one consultations.

Provider Network and Visit Structure

The platform employs nurse practitioners and physicians with menopause training. Visits typically run 30 to 60 minutes and cover symptom assessment, lifestyle counseling, and, when appropriate, hormone therapy prescribing. Patients can also access group education sessions and a library of menopause content.

Insurance and Cash-Pay Model

Elektra accepts several major insurance carriers, which distinguishes it from cash-only competitors. Cash-pay visits generally range from $150 to $350 for an initial consultation, with follow-ups priced lower. The insurance pathway reduces out-of-pocket cost but may limit visit length and follow-up frequency depending on the plan.

The platform's educational layer is genuinely strong. But education and clinical depth are different things. The clinical gaps become apparent when you measure Elektra's prescribing and diagnostic capabilities against what organizations like the North American Menopause Society (NAMS) and the Endocrine Society recommend for comprehensive menopause management.

Hormone Therapy Prescribing: Where the Formulary Falls Short

Elektra providers can prescribe FDA-approved hormone therapy, including oral and transdermal estradiol, micronized progesterone, and combination products. That covers the basics. The gaps emerge in two areas: compounded hormone access and dosing flexibility.

Compounded Hormone Limitations

Many menopause patients require compounded formulations, whether for allergy-related excipient avoidance, dose titration below commercial minimums, or combination preparations like Biest (80/20 estriol/estradiol). The 2022 NAMS position statement acknowledges that while FDA-approved products should be first-line, compounded bioidentical hormones fill a real clinical niche for patients who cannot tolerate standard formulations [1]. Elektra's formulary tilts heavily toward commercial products. Patients needing compounded testosterone cream (a common off-label prescription for hypoactive sexual desire in postmenopausal women) may find that Elektra providers either do not prescribe it or refer externally.

Testosterone Prescribing Gap

This matters because the Global Consensus Position Statement on testosterone therapy for women, published across four endocrine journals in 2019, found that transdermal testosterone at physiologic doses improves sexual function in postmenopausal women (pooled standardized mean difference 0.30, 95% CI 0.16 to 0.44) [2]. A platform that does not routinely prescribe testosterone is missing a treatment supported by Level I evidence.

Narrow Dose Titration Windows

Dose titration flexibility is another concern. The Endocrine Society's 2015 guideline on menopausal HT recommends starting at the lowest effective dose and titrating based on symptom response, with dose adjustments at 4- to 12-week intervals [3]. Commercial patches come in fixed increments (0.025 mg, 0.05 mg, 0.075 mg, 0.1 mg). For a patient who responds partially to 0.05 mg but gets side effects at 0.075 mg, a compounded 0.0625 mg preparation solves the problem. Without compounding access, providers are stuck between undertreating and overtreating.

Diagnostic and Lab Ordering Gaps

Menopause is not just hot flashes. It is a cardiovascular risk inflection point, a bone-density turning point, and a metabolic transition that affects thyroid function, lipid profiles, glucose metabolism, and body composition. Comprehensive menopause care requires diagnostic workup. This is where Elektra's virtual-only model creates friction.

No Integrated Lab Ordering in Most States

Elektra does not operate its own lab network. In most states, patients must obtain lab orders from their primary care physician or visit an external lab service. This creates a care fragmentation problem: the menopause specialist recommends labs, the PCP may not agree on what to order, the patient becomes the coordinator, and results may take weeks to loop back to the treating provider.

Missed Cardiovascular Screening

The 2020 AHA scientific statement on menopause and cardiovascular risk found that the menopause transition is associated with increases in LDL cholesterol (mean increase of 10 to 15%), total cholesterol, and apolipoprotein B independent of aging [4]. The SWAN study (N=1,054) documented that the final menstrual period marks an acceleration in atherosclerotic risk markers that is distinct from chronological aging [5].

A menopause platform that does not integrate lipid panel tracking, ASCVD risk calculation, or blood pressure monitoring is missing a window to intervene on the leading cause of death in postmenopausal women. Elektra's model defers this to the PCP, which means it may never happen if the patient does not have an active primary care relationship.

Bone Density Blind Spot

The USPSTF recommends DXA screening for all women aged 65 and older and for younger postmenopausal women with elevated fracture risk [6]. Elektra cannot order DXA scans. It cannot coordinate FRAX scoring with imaging. For early postmenopausal women losing bone density at 2 to 3% per year (the rate documented in the first 5 years post-menopause [7]), this gap means the platform's care stops where a major long-term risk begins.

State Licensure and Access Limitations

Elektra Health is not available in all 50 states. Telehealth licensure varies by state, and Elektra's provider network does not cover every jurisdiction. Patients in states without coverage simply cannot access the platform. Wait times in covered states range from 1 to 3 weeks for a first appointment, which is better than the 4 to 6 month average reported in a 2021 survey of menopause specialist availability [8], but still a barrier for women in acute symptom distress.

Limited Specialist Depth

The provider network consists primarily of nurse practitioners and a smaller number of physicians. While NPs with menopause training deliver high-quality care for most patients, complex cases (refractory symptoms, contraindications to estrogen, history of hormone-sensitive cancers) often require physician-level expertise in reproductive endocrinology. Elektra does not publicly list fellowship-trained reproductive endocrinologists on its roster.

No In-Person Hybrid Option

Some clinical scenarios require physical examination. Vulvovaginal atrophy assessment, breast examination before initiating HT, and pelvic floor evaluation are difficult to perform virtually. The 2022 NAMS position statement notes that genitourinary syndrome of menopause (GSM) affects up to 84% of postmenopausal women [1], and accurate staging often requires visual and tactile examination. Elektra's purely virtual model cannot accommodate this.

How Elektra Compares to Alternatives

Several telehealth platforms now target the menopause market. Each has a different clinical depth profile.

Versus Multi-Specialty Telehealth Clinics

Platforms that combine menopause care with endocrinology, cardiology referrals, and integrated lab ordering provide a more complete clinical picture. A patient on HT who develops elevated liver enzymes or shifting lipid panels benefits from a provider who can see and act on those labs in the same visit. Elektra's model requires the patient to shuttle between providers.

Versus Compounding-Focused Platforms

Telehealth services that partner directly with compounding pharmacies (like Help Pharmacy or Belmar Pharmacy) can prescribe customized HT formulations, testosterone creams, DHEA suppositories, and combination preparations that Elektra's formulary does not appear to include. For the estimated 10 to 15% of women who cannot tolerate standard commercial HT formulations, this distinction determines whether they receive treatment at all.

Versus NAMS-Certified Practitioner Directories

NAMS maintains a directory of certified menopause practitioners who have passed a competency examination. Patients who find a NAMS-certified provider in their area gain access to someone whose knowledge has been formally tested, often with the ability to order labs, imaging, and referrals within a health system. The trade-off is longer wait times and higher costs in many markets.

The Education Advantage

Where Elektra genuinely leads is patient education. The platform's content library, community sessions, and structured educational programming give patients context that many 15-minute PCP visits do not provide. The SWAN study and others have shown that informed patients adhere better to HT regimens and report higher satisfaction [5]. Education is not a clinical gap for Elektra. It is possibly its greatest strength.

What a Complete Menopause Clinical Model Looks Like

The Endocrine Society's 2015 guideline [3] and the 2022 NAMS position statement [1] together describe a standard of care that includes:

• Symptom assessment with validated instruments (the Menopause Rating Scale or Greene Climacteric Scale)
• Baseline labs: FSH, estradiol, lipid panel, TSH, fasting glucose, HbA1c, CBC, CMP, vitamin D
• Cardiovascular risk stratification: ASCVD 10-year risk score, blood pressure, waist circumference
• Bone density evaluation: FRAX for women under 65, DXA for women 65 and older or those with risk factors
• HT prescribing with full formulary access, including transdermal estradiol, oral and vaginal progesterone, vaginal estrogen, and testosterone when indicated
• Follow-up labs at 3 months (estradiol trough, lipid recheck) and annually thereafter
• Cancer screening coordination: mammography timing relative to HT initiation, endometrial monitoring for women on estrogen-only therapy

Elektra covers the first item well and partially addresses HT prescribing. The remaining items are either absent from the platform's standard workflow or deferred to external providers.

The Insurance Model Creates Its Own Constraints

Accepting insurance is a genuine advantage for patients. Out-of-pocket costs drop, and visits may be covered under preventive care codes. But insurance-based visits come with time constraints. A 2023 analysis in the Journal of General Internal Medicine found that the median insurance-reimbursed telehealth visit lasts 18 minutes, compared to 35 to 45 minutes for cash-pay consultations [9].

Menopause care is not an 18-minute problem. A thorough initial evaluation covering vasomotor symptoms, sleep disturbance, mood changes, sexual health, bone risk, cardiovascular risk, and treatment options requires 45 to 60 minutes. The insurance model may force Elektra providers to triage, addressing the chief complaint while deferring the full clinical picture to follow-up visits that may or may not happen.

Reimbursement Limits Formulary Innovation

Insurance formularies also constrain what providers can prescribe. Compounded hormones are not covered by most commercial plans. Off-label testosterone for women is frequently denied. Even FDA-approved products like the estradiol/progesterone combination pill (TX-001HR, brand name Bijuva) may require prior authorization. The insurance pathway that makes Elektra accessible also narrows its clinical toolkit.

Who Elektra Health Works Best For

The platform serves a specific patient profile well: a perimenopausal or early postmenopausal woman with moderate vasomotor symptoms, no complex medical history, insurance coverage that Elektra accepts, an active PCP who can handle labs and screening, and a preference for education-forward care.

That profile is real and common. But it is not the only menopause patient. Women with treatment-resistant symptoms, osteoporosis risk, cardiovascular concerns, history of VTE or breast cancer, or need for compounded formulations will find that Elektra's model leaves gaps that require supplementation from other providers.

The platform is legitimate. It employs licensed providers. It prescribes evidence-based treatments. It is not a scam or a supplement shop. But "legitimate" and "comprehensive" are different standards, and the distance between them matters when you are managing a transition that affects every organ system in the body.